(MT Newswires) -- Merck Chairman and CEO Robert M. Davis talks about Merck's development of a drug to combat obesity and the diseases it can cause. He also comments on the U.S. approval of Winrevair, a new treatment for a rare and dangerous form of high blood pressure. Finally, he talks about healthcare costs and the Group's investments in oncology, immunology and cardiometabolics.

Bloomberg videos